Discovering Novel Retinal Imaging to Measure Efficacy & Select Patients with Regulatory Decision-Enabling Endpoints

With state-of-the-art AI-assisted technology making retinal imaging 100 times faster, the rapid advancement of technology in ophthalmology, coupled with the strong unmet need for more drugs for retinal diseases, highlights the urgency of continued focus and progress in this space. This need is emphasized by Merck's recent $3 billion acquisition of EyeBio. In light of this, as we move into 2025 and beyond, there is a real need to re-unite the retinal imaging biomarkers and endpoints community to align efforts and propel the field to new heights.

The 3^rd Annual Retinal Imaging Biomarkers & Endpoints Summit is addressing this need head on by uniting clinical scientists, imaging scientists, medical directors, R&D, imaging technology and algorithm engineers once again. They will be sharing case studies and real-world examples of how retinal imaging biomarkers and endpoints are impacting clinical trials, that ultimately save pharma and biotech both time and money, two of the largest challenges facing drug developers in the pivotal work they do.

This event is the perfect bridge of those developing technology and those using the technology to ensure the efficacious development of endpoints for regulatory approval in retinal diseases such as dry and wet AMD, GA, GR and DME.